Last reviewed · How we verify
Tarceva
At a glance
| Generic name | Tarceva |
|---|---|
| Also known as | Erlotinib hydrochloride, OSI-774, Erlotinib, erlotinib, Erlotonib |
| Sponsor | M.D. Anderson Cancer Center |
| Target | AarF domain-containing protein kinase 4, Acyl-CoA dehydrogenase family member 11, Chaperone activity of bc1 complex-like, mitochondrial |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Adenocarcinoma of pancreas
- Non-small cell lung cancer
Common side effects
- Rash
- Diarrhea
- Fatigue
- Anorexia
- Nausea
- ALT elevation (Grade 2)
Serious adverse events
- Deep venous thrombosis (TARCEVA/gemcitabine)
- Grade 3/4 rash
- Grade 3/4 thrombotic events (TARCEVA/gemcitabine)
- Grade 3/4 diarrhea
- Deep venous thrombosis (placebo/gemcitabine)
Key clinical trials
- Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (PHASE1)
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (PHASE1)
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tarceva CI brief — competitive landscape report
- Tarceva updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI